Christopher Thomas Giordano - 16 May 2025 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Role
CEO, Director
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact
Issuer symbol
TENX
Transactions as of
16 May 2025
Net transactions value
$0
Form type
4
Filing time
20 May 2025, 18:50:44 UTC
Previous filing
12 Dec 2024
Next filing
20 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Giordano Christopher Thomas CEO, Director 101 GLEN LENNOX DRIVE, SUITE 300, CHAPEL HILL /s/ S. Halle Vakani, as Attorney-in-Fact 20 May 2025 0001871714

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TENX Stock Option (right to buy) Award $0 +1,400,000 $0.000000 1,400,000 16 May 2025 Common Stock 1,400,000 $5.89 Direct F1
holding TENX Stock Option (right to buy) 157 16 May 2025 Common Stock 157 $3152.00 Direct F2
holding TENX Stock Option (right to buy) 125 16 May 2025 Common Stock 125 $992.00 Direct F3
holding TENX Stock Option (right to buy) 437 16 May 2025 Common Stock 437 $3.55 Direct F4
holding TENX Stock Option (right to buy) 1,250,000 16 May 2025 Common Stock 1,250,000 $5.94 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
F2 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.
F3 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
F4 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.